GTRGEO22 Inhibitors
GTRGEO22 Inhibitors are a class of compounds that target various signaling pathways which GTRGEO22 may be involved in. Staurosporine is a broad-spectrum kinase inhibitor that could inhibit upstream kinases necessary for GTRGEO22 activation, thus preventing its functional activity. LY294002 and Wortmannin are both PI3K inhibitors that prevent the formation of PIP3, a critical second messenger in the PI3K/AKT pathway. If GTRGEO22 functions downstream of PI3K/AKT, these inhibitors would reduce its activity by preventing AKT activation. PD98059 and U0126 are inhibitors of the MEK enzyme, which is part of the MAPK/ERK pathway. If GTRGEO22 is regulated by ERK signaling, these compounds would inhibit its activity by blocking the phosphorylation and activation of ERK.
Rapamycin specifically inhibits mTOR, which is a central regulator of cell growth and metabolism. If GTRGEO22 activity is linked to mTOR signaling, rapamycin would suppress its functional activity by disrupting mTORC1 signaling. SB203580 and SP600125 target the p38 MAPK and JNK signaling pathways, respectively. If GTRGEO22 is activated by either of these MAPK pathways, these inhibitors wouldprevent its activation. Y-27632 targets the Rho-associated protein kinase (ROCK), which is involved in regulating the actin cytoskeleton; inhibiting ROCK may lead to the functional inhibition of GTRGEO22 if it is associated with actin dynamics. Gefitinib and Imatinib, on the other hand, are specific tyrosine kinase inhibitors; gefitinib targets the epidermal growth factor receptor (EGFR) while imatinib targets BCR-ABL, PDGF, and c-Kit.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A potent kinase inhibitor that can inhibit a wide range of protein kinases which may be upstream of GTRGEO22. Inhibition of these kinases could prevent phosphorylation events required for GTRGEO22 activation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that prevents the phosphorylation of PIP2 to PIP3, which could inhibit downstream AKT signaling. If GTRGEO22 activity is AKT-dependent, LY294002 would lead to its functional inhibition. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An MEK inhibitor that blocks the MAPK/ERK pathway. If GTRGEO22's activity is contingent on ERK signaling, PD98059 would inhibit its functional activity by preventing ERK-mediated phosphorylation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that disrupts the mTORC1 pathway, which could lead to reduced protein synthesis and indirectly inhibit GTRGEO22 if it is regulated by mTORC1 signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor that prevents downstream signaling. If GTRGEO22 is activated by p38 MAPK, SB203580 would inhibit its activity by blocking this signaling pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
Another MEK inhibitor that could inhibit ERK activation. If GTRGEO22 requires ERK activity for its function, U0126 would result in decreased GTRGEO22 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A PI3K inhibitor similar to LY294002 that would inhibit AKT activation. This could lead to the inhibition of GTRGEO22 if it is part of the PI3K/AKT pathway. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
An Src family kinase inhibitor that could prevent the activation of downstream proteins that may be required for GTRGEO22 function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK signaling. If GTRGEO22 is downstream of JNK, SP600125 would inhibit its activity by preventing JNK-mediated activation. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A ROCK inhibitor that could inhibit downstream actin cytoskeleton dynamics. If GTRGEO22 is involved in actin remodeling, Y-27632 would impair its functional activity. | ||||||